DCAT - Drug, Chemical & Associated Technologies Association

M&A in the Chemical Industry

Navigating Uncertainty While Unlocking Strategic Opportunities

The CDMO/CMO Report

Driven by increased demand in biologic-based drugs, biologic drug substance manufacturing continues to be an active area of investment by contract development and manufacturing organizations/contract manufacturing organizations (CDMOs/CMOs), including several multi-billion large-scale biomanufacturing projects. What companies are expanding, and where do these expansions stand?

Ramping Up Biomanufacturing Capacity

Biomanufacturing for both traditional biologics and new modalities, such as cell and gene therapies, continues to be an active area of investment for CDMOs/CMOS. Some of the major investments by the larger CMDOs/CMOs are outlined in this article.

Expansions in High-Potency API Manufacturing

DCAT Value Chain Insights rounds up recent expansion activity for highly potent drug substances and drug products.

DCAT Announces New Board of Directors